Advertisement

Topics

Clinical Trials About "Lamisil" RSS

02:00 EDT 18th October 2017 | BioPortfolio

We list hundreds of Clinical Trials about "Lamisil" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Lamisil" on BioPortfolio

We have published hundreds of Lamisil news stories on BioPortfolio along with dozens of Lamisil Clinical Trials and PubMed Articles about Lamisil for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lamisil Companies in our database. You can also find out about relevant Lamisil Drugs and Medications on this site too.

Showing "Lamisil" Clinical Trials, all 6

Relevant

Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg

The objective of this study was to investigate the bioequivalence of Mylan's terbinafine hydrochloride tablets to Novartis' Lamisil® tablets following a single, oral 250 mg (1 x 250 mg) dose administered under fed conditions.


Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg

The objective of this study was to investigate the bioequivalence of Mylan's terbinafine hydrochloride 250 mg tablets to Novartis' Lamisil® 250 mg tablets following a single, oral 250 mg (1 x 250 mg) dose administered under fasting conditions.

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.


Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo

The study shall prove whether 6 consecutive doses of Bifonazole spray show comparable efficacy to a Terbinafine solution applied once.


More From BioPortfolio on "Lamisil"

Quick Search
Advertisement